MyFinsight
Home
Blog
About
Contact
Proceeds from stock
option exercises
$19,194K
Net cash provided by
financing activities
$18,769K
Canceled cashflow
$425K
Net decrease in
cash, cash...
-$212,911K
Canceled cashflow
$18,769K
Purchases of investments
-$233,199K
Stock-based compensation
expense
$16,007K
Accounts payable
$8,824K
Depreciation and
amortization
$2,022K
Other assets and
liabilities
-$1,969K
Operating lease
right-of-use assets
-$615K
Payments on finance
leases
$425K
Net cash provided by
(used in) investing...
-$142,840K
Net cash used in
operating activities
-$88,840K
Canceled cashflow
$233,199K
Canceled cashflow
$29,437K
Maturities of investments
-$250,285K
Net loss
-$69,234K
Deferred revenue
-$34,365K
something is missing
-$125,320K
Purchase of property and
equipment, net
$434K
Accrued expenses and
other current...
-$7,209K
Prepaid expenses and
other current assets
$3,565K
Premiums and discounts on
available-for-sale marketable...
-$2,730K
Operating lease
liabilities
-$1,358K
Back
Back
Cash Flow
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR)
source: myfinsight.com